WallStSmart

Nasdaq Inc (NDAQ)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 3% more annual revenue ($5.40B vs $5.25B). NDAQ leads profitability with a 34.1% profit margin vs 27.5%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

NDAQ

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.5Value: 10.0Quality: 6.5
Piotroski: 5/9

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NDAQUndervalued (+44.4%)

Margin of Safety

+44.4%

Fair Value

$144.61

Current Price

$83.74

$60.87 discount

UndervaluedFair: $144.61Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NDAQ3 strengths · Avg: 9.3/10
Profit MarginProfitability
34.1%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
47.6%10/10

Strong operational efficiency at 47.6%

EPS GrowthGrowth
47.6%8/10

Earnings expanding 47.6% YoY

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

NDAQ2 concerns · Avg: 4.0/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
28.0x4/10

Moderate valuation

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : NDAQ

The strongest argument for NDAQ centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 34.1% and operating margin at 47.6%. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : NDAQ

The primary concerns for NDAQ are PEG Ratio, P/E Ratio.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

NDAQ carries more volatility with a beta of 1.03 — expect wider price swings.

NDAQ is growing revenue faster at 13.4% — sustainability is the question.

NDAQ generates stronger free cash flow (536M), providing more financial flexibility.

Monitor FINANCIAL DATA & STOCK EXCHANGES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (70/100 vs 69/100), backed by strong 27.5% margins and 11.0% revenue growth. NDAQ offers better value entry with a 44.4% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Nasdaq Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?